Optimer Pharmaceuticals Reports Second Quarter 2009 Financi...(armaceuticals Inc. ...)

Date:8/5/2009

armaceuticals, Inc. Consolidated Statements of Operations (unaudited) Three Months Ended Six Months Ended June 30, June 30, ----------------- ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues: Research grants $324,778 $118,797 $407,790 $605,463 Collaborative research agreements 100,000 50,000 100,000 50,000 ------- ------ ------- ------ Total revenues 424,778 168,797 507,790 655,463 Operating expenses: Research and development 10,528,482 6,220,482 19,327,064 13,125,858 Marketing 475,062 913,916 785,348 1,279,484 General and administrative 1,871,309 1,521,446 3,919,809 3,258,497 --------- --------- --------- --------- Total operating expenses 12,874,853 8,655,844 24,032,221 17,663,839 ---------- --------- ---------- ---------- Loss from operations (12,450,075) (8,487,047) (23,524,431) (17,008,376) Interest income and other, net 88,070 433,750 275,038 1,015,034 ------ ------- ------- --------- Net loss $(12,362,005) $(8,053,297) $(23,249,393) $(15,993,342) ============ =========== ============ ============ Basic and diluted net loss per share $(0.37) $(0.29) $(0.73) $(0.57)
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures